Prothena Corporation plc

PRTA

IE00B91XRN20

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-05 EDT			5-day change	1st Jan Change
20.26 ^USD	+0.95%		-1.84%	-44.25%

07-01	Prothena Corporation plc(NasdaqGS:PRTA) added to Russell Small Cap Comp Value Index	CI
07-01	Prothena Corporation plc(NasdaqGS:PRTA) added to Russell 2500 Value Index	CI

Prothena Corporation plc(NasdaqGS:PRTA) added to Russell 3000 Value Index

July 30, 2024

Latest news about Prothena Corporation plc

Prothena Corporation plc(NasdaqGS:PRTA) added to Russell Small Cap Comp Value Index	06-30	CI
Prothena Corporation plc(NasdaqGS:PRTA) added to Russell 2500 Value Index	06-30	CI
Prothena Corporation plc(NasdaqGS:PRTA) added to Russell 3000 Value Index	06-30	CI
Prothena Corporation plc(NasdaqGS:PRTA) added to Russell 2000 Value Index	06-30	CI
Prothena Corporation plc(NasdaqGS:PRTA) added to Russell 3000E Value Index	06-30	CI
Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License	05-28	MT
Prothena Announces Bristol Myers Squibb Opt-In for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration	05-28	CI
RBC Cuts Price Target on Prothena to $28 From $35, Keeps Sector Perform, Speculative Risk	05-09	MT
Earnings Flash (PRTA) PROTHENA CORPORATION Posts Q1 Revenue $50,000	05-08	MT
Prothena Corporation plc Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Prothena Names David Ford as Chief People Officer	03-04	MT
Prothena Appoints David Ford to Newly Created Chief People Officer	03-04	CI
Prothena Corporation plc Announces Board Changes	02-21	CI
Oppenheimer Cuts Prothena Price Target to $80 From $98, Maintains Outperform Rating	02-20	MT
Sector Update: Health Care Stocks Gain Pre-Bell Friday	02-16	MT
RBC Trims Price Target on Prothena to $35 From $36, Keeps Sector Perform, Speculative Risk	02-16	MT
Prothena Posts Q4 Net Loss as Revenue Slumps	02-15	MT
Earnings Flash (PRTA) PROTHENA CORPORATION Reports Q4 Revenue $316,000, vs. Street Est of $2.72M	02-15	MT
Prothena Corporation plc Provides Earnings Guidance for the Year 2024	02-15	CI
Transcript : Prothena Corporation plc, Q4 2023 Earnings Call, Feb 15, 2024	02-15
Prothena Corporation plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-15	CI
RBC Cuts Price Target on Prothena to $36 From $43, Calls Initial Data on PRX012 'Anticlimactic,' Keeps Sector Perform, Speculative Risk	01-25	MT
Deutsche Bank Initiates Coverage on Prothena With Buy Rating, $62 Price Target	12-12	MT
Researchers return to Alzheimer's vaccines, buoyed by recent drug success	11-20	RE
Earnings Flash (PRTA) PROTHENA CORPORATION Posts Q3 Revenue $84.9M, vs. Street Est of $41.7M	11-02	MT

Chart Prothena Corporation plc

Duration

Period

More charts

Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Companyâs pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimerâs disease, Parkinsonâs disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinsonâs disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimerâs disease.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Prothena Corporation plc

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20.26 USD

Average target price

64.75 USD

Spread / Average Target

+219.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PROTHENA CORPORATION PLC	-44.25%	1.09B
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.6B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs